Home Business Viking Therapeutics shares fall 40% on disappointing obesity pill trial data

Viking Therapeutics shares fall 40% on disappointing obesity pill trial data

by admin

The results could reinforce the dominance of Eli Lilly and Novo Nordisk in the booming market for weight loss and diabetes drugs.Original Article

You may also like

Leave a Comment

5 × two =